The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study
Current Medical Research and OpinionPublished 16 July 2004
Triantafyllos Didangelos, Anastasia Thanopoulou, Stavros Bousboulas, Christos Sambanis, Vasilios G. Athyros, Elefteria Spanou
Citations69
SJR quartileQ2
SJR score0.79
SNIP0.76
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Orlistat plus HCD favourably modified several cardiovascular risk factors in patients with both MetSyn and type 2 DM, which might partly offset the excess cardiovascular risk and improve outcome in this patient population.
Abstract
Orlistat plus HCD favourably modified several cardiovascular risk factors in patients with both MetSyn and type 2 DM. These effects might partly offset the excess cardiovascular risk and improve outcome in this patient population.
Keywords
Medicine
JAMASummary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
27,886 Citations1993Scott M. Grundy
Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
JAMAExecutive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
25,992 Citations2001Evaluation Expert Panel on Detection
ScienceAdipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
7,453 Citations1993Gökhan S. Hotamışlıgil, Narinder S. Shargill +1 more
A role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity is indicated.
JAMAThe Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men
5,041 Citations2002Hanna‐Maaria Lakka
Cardiovascular disease and all-cause mortality are increased in men with the metabolic syndrome, even in the absence of baseline CVD and diabetes, according to the Kuopio Ischaemic Heart Disease Risk Factor Study.
Diabetes CareCardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
4,779 Citations2001Bo Isomaa, Peter Almgren +6 more
The WHO definition of the metabolic syndrome identifies subjects with increased cardiovascular morbidity and mortality and offers a tool for comparison of results from diferent studies.
Diabetes CareXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
1,902 Citations2004Jarl Torgerson, Jonathan Hauptman +2 more
Compared with lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years and produced greater weight loss in a clinically representative obese population.
CirculationMetabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
1,513 Citations2003Naveed Sattar, Allan Gaw +9 more
A modified NCEP metabolic syndrome definition predicts CHD events, and, more strikingly, new-onset diabetes, and thus helps identify individuals who may receive particular benefit from lifestyle measures to prevent these diseases.
JAMASerum Uric Acid and Cardiovascular Mortality
1,507 Citations2000Jing Fang, Michael H. Alderman
Increased serum uric acid levels had a positive relationship to cardiovascular mortality in men and women and in black and white persons and stratifying by cardiovascular risk status, diuretic use, and menopausal status confirmed this relationship.
DiabetesNCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older
1,485 Citations2003Charles M. Alexander, Pamela B. Landsman +2 more
Annals of Internal MedicineMedical Hazards of Obesity
1,384 Citations1993F. Xavier Pi‐Sunyer
Obesity occurring early in life affects intervening risk factors such as diabetes and hypertension much more strongly than that occurring later in life, when these risk factors become more important variables.
The LancetRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
1,203 Citations1998Lars Sjöström, Aila Rissanen +5 more
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
DiabetologiaPrevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malm� feasibility study
1,105 Citations1991Karl‐Fredrik Eriksson, F. Lindg�rde
It is concluded that long-term intervention in the form of diet and physical exercise is feasible even on a large scale, and that substantial metabolic improvement can be achieved which may contribute to prevent or postpone manifest diabetes.
NatureLeptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
1,051 Citations1999Iichiro Shimomura, Robert E. Hammer +3 more
It is shown that insulin resistance in lipodystrophic mice can be overcome by a continuous systemic infusion of low doses of recombinant leptin, an effect that is not mimicked by chronic food restriction.
JAMAWeight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat
937 Citations1999Michael Davidson, Jonathan Hauptman +9 more
Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.
CirculationEffects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).
883 Citations1994William L. Haskell, Edwin L. Alderman +8 more
Intensive multifactor risk reduction conducted over 4 years favorably altered the rate of luminal narrowing in coronary arteries of men and women with coronary artery disease and decreased hospitalizations for clinical cardiac events.
BMJUltrasound scanning in the detection of hepatic fibrosis and steatosis.
850 Citations1986S.H. Saverymuttu, A.E.A. Joseph +1 more
As hepatic steatosis is the earliest change in alcoholic liver disease and seems to be of prognostic importance for the development of cirrhosis, ultrasound scanning provides an effective screening procedure, particularly in the occult alcoholic, who often presents with non-specific gastrointestinal complaints.
CirculationAssociation of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey
799 Citations2003John K. Ninomiya, Gilbert L’Italien +4 more
The results indicate a strong, consistent relationship of the metabolic syndrome with prevalent myocardial infarction and stroke.
DiabetesThe perils of portliness: causes and consequences of visceral adiposity.
745 Citations2000Carl Montague, Stephen O’Rahilly
A summary of the growing body of data relevant to genetic and environmental determinants of human fat topography and of the molecular mechanisms linking visceral adiposity to degenerative metabolic and vascular disease is attempted.
DiabetesThe Relation of Markers of Inflammation to the Development of Glucose Disorders in the Elderly
541 Citations2001Joshua I. Barzilay, Linn Abraham +5 more
Inflammation, as measured by CRP levels, is associated with the development of diabetes in the elderly, and understanding the role of inflammation in the pathogenesis of glucose Disorders in this age-group may lead to better classification and treatment of glucose disorders among them.
The American Journal of CardiologyThe metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
531 Citations2004Cynthia J. Girman, Thomas Rhodes +7 more
It is demonstrated that the metabolic syndrome is associated with increased risk of MCEs in both hypercholesterolemic patients with coronary heart disease in 4S and in those with low high-density lipoprotein cholesterol but without coronaryHeart disease in AFCAPS/TexCAPS.
Current Medical Research and OpinionTreatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
529 Citations2002Vasilios G. Athyros, Athanasios A. Papageorgiou +6 more
Long-term treatment of CHD patients with atorvastatin to achieve NCEP lipid targets significantly reduces total and coronary mortality, coronary morbidity and stroke, in comparison to patients receiving 'usual' medical care.
AtherosclerosisThe metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study
478 Citations2004Earl S. Ford
Three criteria of the metabolic syndrome-excess weight, hypertriglyceridemia, and low high-density lipoprotein cholesterol concentration-were not independently associated with any of the outcomes.
Annals of Internal MedicineTreatment of Obesity by Moderate and Severe Caloric Restriction: Results of Clinical Research Trials
473 Citations1993Thomas A. Wadden
The effectiveness of moderate caloric restriction was assessed by examining all studies published in four behavioral journals in 1974 and 1978 and from 1984 to 1990 and all controlled studies of severe caloric restriction that included follow-up data were reviewed.
Diabetes CareComponents of the Metabolic Syndrome and Risk of Cardiovascular Disease and Diabetes in Beaver Dam
469 Citations2002Ronald Klein, Ronald Klein +1 more
Components of the metabolic syndrome are common and are associated with incident cardiovascular disease and diabetes after 5 years, and interventions to alter BMI, lipid levels, and blood pressure may decrease incident diabetes and cardiovascular disease.
Annals of Internal MedicineShort-Term Medical Benefits and Adverse Effects of Weight Loss
393 Citations1993F. Xavier Pi‐Sunyer
The Framingham study, a prospective, epidemiologic study of a typical American town, showed that blood pressure decreased with weight loss and an improvement in prevailing blood glucose levels is shown by a decrease in the levels of glycated hemoglobin.
American Journal of EpidemiologySyndrome X and Mortality: A Population-based Study
387 Citations1998Maurizio Trevisan, J Liu +2 more
Data from a large population-based epidemiologic investigation indicate that the presence of a full cluster of metabolic abnormalities from syndrome X is an important risk factor for cardiovascular disease and all-cause mortality in both men and women, but that the low prevalence of such a cluster in the population reduces the public health impact of syndrome X.
Internal MedicineRole of Adipocytokines on the Pathogenesis of Atherosclerosis in Visceral Obesity.
383 Citations1999Tohru Funahashi, Tadashi Nakamura +7 more
A systematic search of active genes in adipose tissue found that plasminogen activator-1 (PAI-1), which is a regulator of the fibrinolytic system, was overexpressed in the visceral fat in an animal model of obesity and may play some role in thrombotic vascular disease in visceral obesity.
PubMedLong-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women.
381 Citations1989F. Matthew Kramer, Robert W. Jeffery +2 more
Although significant mean weight loss was evident at long-term follow-up, a negatively accelerating pattern of weight regain was the predominant outcome and consistent sex differences were found, with women having better weight loss maintenance than men.
Digestive and Liver DiseaseIncreased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases
339 Citations2002Ulrik Mathiesen, L Franzén +6 more
Assessment of liver echogenicity is of value for detection or exclusion of moderate to pronounced fatty infiltration but cannot be relied upon in diagnosing fibrosis, not even cirrhosis in asymptomatic patients with mild to moderately elevated liver transaminases.
Diabetes CareClinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
312 Citations2002David E. Kelley, George A. Bray +5 more
Orlistat therapy produces clinically significant weight loss, with improvements in glycemic control and cardiovascular disease risk factors, in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy.
The American Journal of CardiologyClinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity
212 Citations2002Peter O. Kwiterovich
The metabolic syndrome, as defined by ATP III, incorporates a number of the components of these syndromes, including insulin resistance and intra-abdominal fat, and appears to be part of this atherogenic syndrome.
Diabetic MedicinePreventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view
208 Citations2003Paul Zimmet, Jonathan E. Shaw +1 more
There needs to be a realistic approach to interventions in both developed and developing nations, and in ethnic groups where a better understanding of the socio‐economic, cultural and demographic issues and perceptions surrounding chronic diseases such as diabetes is required.
American Journal of Kidney DiseasesEffect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study
208 Citations2004Vasilios G. Athyros, Moses Elisaf +6 more
Data suggest that SUA level is an independent predictor of CHD recurrent events, thus offsetting an additional factor associated with CHD risk.
Journal of Internal MedicineThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
205 Citations2000Folke Lindgärde
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients in the Swedish Multimorbidity Study is illustrated.
MetabolismModest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines
189 Citations2004Georgios Valsamakis, Philip G. McTernan +6 more
It is concluded that modest weight loss (>5%) after medical treatment in a routine obesity hospital clinic is associated with improvements in insulin sensitivity and lipid profile and also associated with potentially favourably changes in serum adipocytokines, particularly in a rise of serum adiponectin.
Diabetes CareEfficacy of metformin in the treatment of NIDDM. Meta-analysis.
187 Citations1999K. B. JOHANSEN
Metformin and sulfonylurea have an equal effect on fasting blood glucose and glycosylated hemoglobin, but the body weight is significantly lower after metformin compared with sulfonyLurea treatment because of an increase in body weight after sulfony luresa treatment.
AtherosclerosisDiet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors
185 Citations1993Mai-Lis Helle ́nius, Ulf dé Fairé +3 more
It is concluded that even with rather moderate changes in diet and exercise, several important cardiovascular risk factors can be affected and that diet andercise were about equally effective in reducing cardiovascular risk.
DiabetologiaNo excess 12-year mortality in men with impaired glucose tolerance who participated in the Malm� Preventive Trial with diet and exercise
182 Citations1998Karl‐Fredrik Eriksson, F. Lindg�rde
The findings suggest that a long-term intervention programme, with an emphasis on lifestyle changes, including dietary counselling and physical exercise, will reduce mortality in subjects with IGT who are at an increased risk of both developing NIDDM and of premature death due to IHD and other causes.
Diabetes Obesity and MetabolismEvaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
165 Citations2002A. Gokcel, Yüksel Gümürdülü +5 more
A randomized, prospective clinical trial is designed to study the efficacy and safety of 10“mg sibutramine twice daily, and compare this treatment with 120 mg orlistat three times daily (tid) and 850‰mg metformin (bid).
Diabetes Obesity and MetabolismThe prevalence of the metabolic syndrome in Greece: The MetS‐Greece Multicentre Study
161 Citations2004Vasilios G. Athyros, Vasilios I. Bouloukos +9 more
This study highlights the importance of identifying and treating patients with the metabolic syndrome (MetS) to prevent cardiovascular disease (CVD) and progression to diabetes mellitus.
The American Journal of CardiologyPreventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome
150 Citations2003Nathan D. Wong, Jose R. Pio +4 more
Many CHD events in patients with MetS may be preventable by nominal or optimal control of lipids and/or blood pressure.
Diabetes Obesity and MetabolismThe effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial
148 Citations2002M Hanefeld, G. Sachse
The aim of this study is to assess the long‐term effects of orlistat on body weight, glycaemic control and cardiovascular risk factors in overweight patients with type 2 diabetes.
Diabetes CareEfficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study
147 Citations1994Juergen Hoffmann, M. Spengler
Acarbose and glibenclamide are effective drugs for the monotherapy of NIDDM patients when diet alone fails and postprandial insulin increase has been shown to be associated with increased risk for cardiovascular disease.
The American Journal of MedicineEfficacy of 24-Week Monotherapy With Acarbose, Metformin, or Placebo in Dietary-Treated NIDDM Patients
146 Citations1997Jürgen Hoffmann, M. Spengler
Acarbose and metformin are effective drugs for the first line monotherapy of patients with NIDDM and both active drugs showed the same improvement of efficacy criteria compared with placebo.
Current Medical Research and OpinionThe GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
123 Citations2002Dimitri P. Mikhailidis, Anthony S. Wierzbicki
Among CHD patients, those with MetS benefited more from statin treatment than those without MetS, and this benefit could be partially attributed to favourable changes in e-GFR and SUA levels probably induced bystatin treatment.
PubMedThree-year follow-up of participants in a commercial weight loss program. Can you keep it off?
92 Citations1996Francine Grodstein, Rachel Levine +4 more
AngiologyEarly Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus
85 Citations2003Vasilios G. Athyros, Athanasios A. Papageorgiou +5 more
In CHD patients with DM, structured care of dyslipidemia with atorvastatin to achieve the NCEP LDL-C treatment goal, reduces all-cause and coronary mortality, coronary morbidity, and stroke by more than one half within a 3-year period, in comparison to usual care.
Archives of Internal MedicineThree-Year Follow-up of Participants in a Commercial Weight Loss Program
61 Citations1996Francine Grodstein
The frequency of exercise after the diet program was the strongest predictor of weight loss maintenance, while television viewing predicted a gain in weight.
Journal of Cardiopulmonary RehabilitationLifestyle Modification Program in Management of Patients With Coronary Artery Disease: The Clinical Experience in a Tertiary Care Hospital
59 Citations1999John C. Rutledge, Dianne A. Hyson +4 more
Multidisciplinary lifestyle modification programs addressing cardiovascular risk factors are known to have a significant impact upon cardiac risk factors in patients with coronary atherosclerosis and data show that these changes can be accomplished in independent-living patients in a program offered through a routine cardiology service.
Diabetic MedicinePredictors of insulin sensitivity in Type 2 diabetes mellitus
55 Citations2002Enzo Bonora, Giovanni Targher +13 more
The objective is to establish whether isolated Type 2 diabetes (i.e. diabetes without overweight, dyslipidaemia and hypertension) is a condition of insulin resistance and to identify the independent predictors of insulin sensitivity in Type 1 diabetes.
Journal of Diabetes and its ComplicationsTreating dyslipidaemia in non-insulin-dependent diabetes mellitus — a special reference to statins
30 Citations2001John A. Papadakis, Haralampos Milionis +2 more
Results from post hoc analyses of diabetic subgroups in the large intervention trials suggest that some statins significantly reduce the risk for IHD-related mortality/morbidity, but it is not sure if these benefits apply to all diabetic subjects or only to those who already have IHD.